Takayuki Yoshino on the DESTINY-CRC01 trial

The Lancet Oncology in conversation with
01/06/2021 5 min
Takayuki Yoshino on the DESTINY-CRC01 trial

Listen "Takayuki Yoshino on the DESTINY-CRC01 trial"

Descargar episodio

Episode Synopsis

Takayuki Yoshino (National Cancer Center Hospital East, Kashiwa, Japan) discusses the DESTINY-CRC01 trial on trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00086-3/fulltextTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

More episodes of the podcast The Lancet Oncology in conversation with

Andre Pfob and Peter Dubsky on The Lucerne Toolbox 3 25/11/2025
Gary Rodin on The human crisis in cancer: a Lancet Oncology Commission 02/11/2025
Matthias Preusser on the phase 2 TUXEDO-3 trial 27/10/2025
Andrea Necchi on TAR-200 plus cetrelimab as neoadjuvant therapy in patients with muscle-invasive bladder cancer 29/09/2025
Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas 02/09/2025
Jinming Li on patterns in genomic mutations among patients with early-onset colorectal cancer 28/07/2025
Abdalla Awidi on cancer control in the Middle East 11/06/2025
ASCO 2025 Debrief 11/06/2025
Caroline Robert on treatments for patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN trial) 28/05/2025
Richard Bryant on transperineal vs transrectal biopsy for prostate cancer 30/04/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA